A Phase II Clinical Trial of Tucidinostat in Combination With Apatinib in Patients With Relapsed or Refractory Osteosarcoma

Wuhan Union Hospital, China0 sites46 target enrollmentJanuary 2024

ConditionsOsteosarcoma

InterventionsTucidinostat, Apatinib

DrugsTucidinostat, Apatinib

Overview

Phase: Phase 2
Intervention: Tucidinostat, Apatinib
Conditions: Osteosarcoma
Sponsor: Wuhan Union Hospital, China
Enrollment: 46
Primary Endpoint: 6-month progression-free survival rate
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This phase II study was designed to assess the efficacy and safety of the combination of Apatinib, Tucidinostat (chidamide), a histone deacetylase inhibitor in relapsed or refractory osteosarcoma patients.

Registry

clinicaltrials.gov

Start Date

January 2024

End Date

December 2025

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Wuhan Union Hospital, China

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age ≥10 years, ≤ 75 years;
•Histologically confirmed Advanced classic osteosarcoma with unresectable recurrence or metastatic disease ；
•Prior treatment consisted of standard chemotherapy agents including doxorubicin, cisplatin, methotrexate, and ifosfamide;
•Eastern Collaborative Oncology Group (ECOG) 0\~2；
•Tumor size is measurable according to RECIST1.1 criteria；
•Adequate organ function；
•Life expectancy is more than 3 months；
•Willing and able to provide written informed consent.

Exclusion Criteria

•Previously exposed to histone deacetylase inhibitors or angiogenesis inhibitors;
•Urine protein≥ ++;
•FBG\>10mmol/L;
•Uncontrolled blodd pressure (ystolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 90 mmHg);
•Known active CNS metastases and/or carcinomatous meningitis;
•Not able to take medicine orally;
•Coagulant function abnormality (PT\>16s, APTT\> 43s, TT\>21s, FIB）\<2g/L);
•Uncontrolled clinically significant systemic diseases, including active infection, unstable angina, angina occurred within 3 months,≥ NYHA II congestive heart failure, myocardial infarction occurred within 6 months, severe arrhythmia, liver, kidney, or metabolic disease;
•Major surgery received or severe traumatic injury, fracture, or ulcer occurred within 4 weeks of the first dose of study medication.